In several other tumor types besides lung cancer, ALK genomic alterations have been identified as potential oncogenic drivers, meaning that cancers in different organs can be targeted for treatment with ALK inhibitors regardless of their cell of origin. The gene discussed is ALK; the disease is lung cancer.